Tomohiro Higa, Senior Vice President of Finance at Tenaya Therapeutics, Inc., reported a sale of company stock that totaled $1,177. The transaction occurred on May 18, 2026.
Specifically, Mr. Higa disposed of 1,485 shares of common stock. The selling price for these shares was $0.7932 per share. These units were sold to cover tax withholding obligations that arose from the vesting of restricted stock units (RSUs), which had been awarded on August 15, 2024.
This reported sale comes against a backdrop of recent market movement for Tenaya Therapeutics. While the company's stock has experienced a decline of 21% over the preceding week, it maintains an overall gain of 61% when looking at performance across the last year.
Current Holdings and Valuation Insights
Following the disposition of these shares, Mr. Higa currently holds 118,267 shares of Tenaya Therapeutics common stock. This total is comprised of 67,938 shares that are anticipated to be issued to him upon the future vesting of restricted stock units.
Independent analysis from InvestingPro suggests that the company's stock appears undervalued at its current trading levels, with additional detailed insights available to subscribers interested in valuation metrics.
Beyond the recent executive transaction and stock performance data, Tenaya Therapeutics has provided several significant updates regarding its therapeutic pipeline. The company recently reported interim results stemming from its RIDGE-1 Phase 1b/2 clinical trial. This trial focused on evaluating the gene therapy drug TN-401 in adult patients diagnosed with arrhythmogenic right ventricular cardiomyopathy.
The findings from this specific study were notable for demonstrating promising reductions in premature ventricular contractions among the participants included in the trial. In addition to these interim results, Tenaya plans to present detailed clinical data derived from the RIDGE-1 trial at an upcoming major medical event: the American Society of Gene and Cell Therapy Annual Meeting.
Furthermore, the company's research efforts extend to its HDAC6 inhibitor, TN-301. In preclinical models designed for Duchenne muscular dystrophy, this compound demonstrated improved muscle function. Crucially, these findings indicated that TN-301 performed in certain aspects better than the already approved drug, givinostat.
Analyst Sentiment and Future Catalysts
The ongoing development activities have been met with sustained positive attention from financial analysts. Following Tenaya’s fourth-quarter 2025 financial results, both William Blair and Leerink Partners reiterated their favorable ratings on the company.
William Blair specifically highlighted regulatory alignment as a key factor expected to act as a catalyst for the stock. Meanwhile, Leerink Partners maintained its price target at $2.00 following the review of the recent quarterly financials.
These various developments - including promising clinical outcomes and positive analyst coverage - underscore Tenaya’s continuous commitment to advancing multiple therapeutic agents within its pipeline. The overall picture paints a narrative of ongoing scientific progress alongside specific short-term stock movements driven by executive activity and market fluctuations.